$10.74
1.51% yesterday
NYSE, Sep 27, 10:01 pm CET
ISIN
US05380C1027
Symbol
RCEL
Sector

AVITA Therapeutics Stock price

$10.74
+1.58 17.25% 1M
-5.76 34.91% 6M
-2.98 21.72% YTD
-3.64 25.31% 1Y
-7.97 42.60% 3Y
-25.41 70.29% 5Y
+2.14 24.88% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.16 1.51%
ISIN
US05380C1027
Symbol
RCEL
Sector

Key metrics

Market capitalization $262.84m
Enterprise Value $253.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.69
P/S ratio (TTM) P/S ratio 4.85
P/B ratio (TTM) P/B ratio 11.48
Revenue growth (TTM) Revenue growth 32.53%
Revenue (TTM) Revenue $54.14m
EBIT (operating result TTM) EBIT $-133.65m
Free Cash Flow (TTM) Free Cash Flow $-57.54m
Cash position $54.06m
EPS (TTM) EPS $-1.95
P/E forward negative
P/S forward 3.82
EV/Sales forward 3.68
Short interest 5.65%
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AVITA Therapeutics forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a AVITA Therapeutics forecast:

Buy
67%
Hold
33%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
54 54
33% 33%
100%
- Direct Costs 7.53 7.53
12% 12%
14%
47 47
37% 37%
86%
- Selling and Administrative Expenses 158 158
207% 207%
292%
- Research and Development Expense 21 21
26% 26%
39%
-133 -133
287% 287%
-245%
- Depreciation and Amortization 1.15 1.15
29% 29%
2%
EBIT (Operating Income) EBIT -134 -134
273% 273%
-247%
Net Profit -50 -50
63% 63%
-92%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
15 days ago
VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O'Toole, Chief Financial Officer, will present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m.
Neutral
GlobeNewsWire
17 days ago
VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024.
Neutral
Seeking Alpha
about one month ago
RECELL GO's launch increased SG&A expenses, contributing to AVITA Medical, Inc.'s higher net losses in Q2 2024. Despite lowering its 2024 revenue guidance, AVITA Medical still anticipates significant year-over-year growth of 37-41%. AVITA Medical's cash runway is approximately nine months, with $54.1 million in cash and securities available as of June 30, 2024.
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 207
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today